Effect of ionic strength and pH on the physical and chemical stability of a monoclonal antibody antigen-binding fragment

Journal of Pharmaceutical Sciences

Volumn 102, Issue 8, 2013, Pages 2520-2537

  Wang, Tingting ^a   Kumru, Ozan S ^a   Yi, Li ^b   Wang, Y John ^b   Zhang, Jennifer ^b   Kim, Jae Hyun ^a   Joshi, Sangeeta B ^a   Middaugh, C Russell ^a   Volkin, David B ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b GENENTECH INC   (United States)

Author keywords

Antigen binding fragments (Fab); Asp isomerization; Chemical stability; Formulation; IgG antibodies; Monoclonal antibodies; Physical stability; Protein aggregation; Salt; stabilization

Indexed keywords

8 ANILINO 1 NAPHTHALENESULFONIC ACID; ASPARAGINE; EXCIPIENT; MONOCLONAL ANTIBODY; SODIUM CHLORIDE;

ANTIGEN BINDING; ARTICLE; CIRCULAR DICHROISM; COMPLEMENTARITY DETERMINING REGION; CONCENTRATION (PARAMETERS); DIFFERENTIAL SCANNING CALORIMETRY; FLUORESCENCE; FLUORESCENCE SPECTROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ION EXCHANGE CHROMATOGRAPHY; IONIC STRENGTH; ISOMERIZATION; LIGHT SCATTERING; OPTICAL DENSITY; PH; PHYSICAL CHEMISTRY; TELECOMMUNICATION; TURBIDITY;

EID: 84881028178     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23645     Document Type: Article

References (62)

1. Chan AC, Carter PJ. 2010. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 10(5):301-316.
2. Zhou H, Mascelli MA. 2011. Mechanisms of monoclonal antibody-drug interactions. Annu Rev Pharmacol Toxicol 51:359-372.
3. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. 2005. Monoclonal antibody successes in the clinic. Nat Biotechnol 23(9):1073-1078.
4. Nelson AL, Reichert JM. 2009. Development trends for therapeutic antibody fragments. Nat Biotechnol 27(4):331-337.
5. Verma R, Boleti E, George AJ. 1998. Antibody engineering: Comparison of bacterial, yeast, insect and mammalian expression systems. J Immunol Methods 216(1-2):165-181.
6. Harris RJ, Kabakoff B, Macchi FD, Shen FJ, Kwong M, Andya JD, Shire SJ, Bjork N, Totpal K, Chen AB. 2001. Identification of multiple sources of charge heterogeneity in a recombinant antibody. J Chromatogr B Biomed Sci Appl 752(2):233-245.
7. Diepold K, Bomans K, Wiedmann M, Zimmermann B, Petzold A, Schlothauer T, Mueller R, Moritz B, Stracke JO, Mølhøj M, Reusch D, Bulau P. 2012. Simultaneous assessment of Asp isomerization and Asn deamidation in recombinant antibodies by LC-MS following incubation at elevated temperatures. PloS One 7(1):e30295.
8. Sreedhara A, Cordoba A, Zhu Q, Kwong J, Liu J. 2012. Characterization of the isomerization products of aspartate residues at two different sites in a monoclonal antibody. Pharm Res 29(1):187-197.
9. Middaugh CR, Litman GW. 1987. Atypical glycosylation of an IgG monoclonal cryoimmunoglobulin. J Biol Chem 262(8):3671-3673.
10. Wei Z, Feng J, Lin HY, Mullapudi S, Bishop E, Tous GI, Casas-Finet J, Hakki F, Strouse R, Schenerman MA. 2007. Identification of a single tryptophan residue as critical for binding activity in a humanized monoclonal antibody against respiratory syncytial virus. Anal Chem 79(7):2797-2805.
11. Qi P, Volkin DB, Zhao H, Nedved ML, Hughes R, Bass R, Yi SC, Panek ME, Wang D, Dalmonte P, Bond MD. 2009. Characterization of the photodegradation of a human IgG1 monoclonal antibody formulated as a high-concentration liquid dosage form. J Pharm Sci 98(9):3117-3130.
12. Huang L, Lu J, Wroblewski VJ, Beals JM, Riggin RM. 2005. In vivo deamidation characterization of monoclonal antibody by LC/MS/MS. Anal Chem 77(5):1432-1439.
13. Yan BX, Steen S, Hambly D, Valliere-Douglass J, Vanden Bos T, Smallwood S, Yates Z, Arroll T, Han Y, Gadgil H, Latypov RF, Wallace A, Lim A, Kleemann GR, Wang W, Balland A. 2009. Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1 heavy chain. J Pharm Sci 98(10):3509-3521.
14. Rehder DS, Chelius D, McAuley A, Dillon TM, Xiao G, Crouse-Zeineddini J, Vardanyan L, Perico N, Mukku V, Brems DN, Matsumura M, Bondarenko PV. 2008. Isomerization of a single aspartyl residue of anti-epidermal growth factor receptor immunoglobulin gamma2 antibody highlights the role avidity plays in antibody activity. Biochem 47(8):2518-2530.
15. Breen ED, Curley JG, Overcashier DE, Hsu CC, Shire SJ. 2001. Effect of moisture on the stability of a lyophilized humanized monoclonal antibody formulation. Pharm Res 18(9):1345-1353.
16. Zhang J, Yip H, Katta V. 2011. Identification of isomerization and racemization of aspartate in the Asp-Asp motifs of a therapeutic protein. Anal Biochem 410(2):234-243.
17. Wakankar AA, Borchardt RT. 2006. Formulation considerations for proteins susceptible to asparagine deamidation and aspartate isomerization. J Pharm Sci 95(11):2321-2336.
18. Wakankar AA, Borchardt RT, Eigenbrot C, Shia S, Wang YJ, Shire SJ, Liu JL. 2007. Aspartate isomerization in the complementarity-determining regions of two closely related monoclonal antibodies. Biochem 46(6):1534-1544.
19. Chu GC, Chelius D, Xiao G, Khor HK, Coulibaly S, Bondarenko PV. 2007. Accumulation of succinimide in a recombinant monoclonal antibody in mildly acidic buffers under elevated temperatures. Pharm Res 24(6):1145-1156.
20. Yi L, Beckley N, Gikanga B, Zhang J, Wang YJ, Chih HW, Sharma VK. Isomerization of Asp-Asp motif in model peptides and a monoclonal antibody Fab fragment. J Pharm Sci 102(3):947-959.
21. Raymond T, Jenkins N. 2011. Quality issues arising from post-translational modification of recombinant antibodies. In Antibody expression and production; Al-Rubeai M, Ed. Vol. VII. Springer Link, Houten, Netherlands, 293-303.
22. Cacia J, Keck R, Presta LG, Frenz J. 1996. Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: Identification and effect on binding affinity. Biochem 35(6):1897-1903.
23. Wakankar AA, Liu J, Vandervelde D, Wang YJ, Shire SJ, Borchardt RT. 2007. The effect of cosolutes on the isomerization of aspartic acid residues and conformational stability in a monoclonal antibody. J Pharm Sci 96(7):1708-1718.
24. Al-Abdulla I, Garnvwa JM, Rawat S, Smith DS, Landon J, Nasidi A. 2003. Formulation of a liquid ovine Fab-based antivenom for the treatment of envenomation by the Nigerian carpet viper (Echis ocellatus). Toxicon 42(4):399-404.
25. Lam XM, Lai WG, Chan EK, Ling V, Hsu CC. 2011. Site-specific tryptophan oxidation induced by autocatalytic reaction of polysorbate 20 in protein formulation. Pharm Res 28(10):2543-2555.
26. Ye H. 2006. Simultaneous determination of protein aggregation, degradation, and absolute molecular weight by size exclusion chromatography-multiangle laser light scattering. Anal Biochem 356(1):76-85.
27. Kueltzo LA, Ersoy B, Ralston JP, Middaugh CR. 2003. Derivative absorbance spectroscopy and protein phase diagrams as tools for comprehensive protein characterization: A bGCSF case study. J Pharm Sci 92(9):1805-1820.
28. Maddux NR, Joshi SB, Volkin DB, Ralston JP, Middaugh CR. 2011. Multidimensional methods for the formulation of biopharmaceuticals and vaccines. J Pharm Sci 100(10):4171-4197.
29. Alsenaidy MA, Wang T, Kim JH, Joshi SB, Lee J, Blaber M, Volkin DB, Middaugh CR. 2012. An empirical phase diagram approach to investigate conformational stability of "second-generation" functional mutants of acidic fibroblast growth factor-1. Protein Sci 21(3):418-432.
30. Hu L, Joshi SB, Andra KK, Thakkar SV, Volkin DB, Bann JG, Middaugh CR. 2012. Comparison of the structural stability and dynamic properties of recombinant anthrax protective antigen and its 2-fluorohistidine-labeled analogue. J Pharm Sci 101(11):4118-4128.
31. Kim JH, Iyer V, Joshi SB, Volkin DB, Middaugh CR. 2012. Improved data visualization techniques for analyzing macromolecule structural changes. Protein Sci 21(10):1540-1553.
32. Li CH, Nguyen X, Narhi L, Chemmalil L, Towers E, Muzammil S, Gabrielson J, Jiang Y. 2011. Applications of circular dichroism (CD) for structural analysis of proteins: Qualification of near- and far-UV CD for protein higher order structural analysis. J Pharm Sci 100(11):4642-4654.
33. Priddy TS, Middaugh CR, Carlson GM. 2007. Electrostatic changes in phosphorylase kinase induced by its obligatory allosteric activator Ca2+. Protein Sci 16(3):517-527.
34. Radkiewicz JL, Zipse H, Clarke S, Houk KN. 2001. Neighboring side chain effects on asparaginyl and aspartyl degradation: An ab initio study of the relationship between peptide conformation and backbone NH acidity. J Am Chem Soc 123(15):3499-3506.
35. Timasheff SN. 1995. Solvent stabilization of protein structure. Methods Mol Biol 40:253-269.
36. Kohn WD, Kay CM, Hodges RS. 1997. Salt effects on protein stability: Two-stranded alpha-helical coiled-coils containing inter- or intrahelical ion pairs. J Mol Biol 267(4):1039-1052.
37. Wang W. 1999. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm 185(2):129-188.
38. Zhang Y, Cremer PS. 2006. Interactions between macromolecules and ions: The Hofmeister series. Curr Opin Chem Biol 10(6):658-663.
39. Timasheff SN. 1992. Stabilization of protein structure by solvent additives. In Stability of protein pharmaceuticals, Part B; TJAhern, MCManning, Eds. Plenum Press. New York, NY. 265-285.
40. Arosio P, Jaquet B, Wu H, Morbidelli M. 2012. On the role of salt type and concentration on the stability behavior of a monoclonal antibody solution. Biophys Chem 168-169:19-27.
41. Gokarn YR, Fesinmeyer RM, Saluja A, Razinkov V, Chase SF, Laue TM, Brems DN. 2011. Effective charge measurements reveal selective and preferential accumulation of anions, but not cations, at the protein surface in dilute salt solutions. Protein Sci 20(3):580-587.
42. Fesinmeyer RM, Hogan S, Saluja A, Brych SR, Kras E, Narhi LO, Brems DN, Gokarn YR. 2009. Effect of ions on agitation- and temperature-induced aggregation reactions of antibodies. Pharm Res 26(4):903-913.
43. Saso L, Valentini G, Grippa E, Leone MG, Silvestrini B. 1998. Effect of selected substances on heat-induced aggregation of albumin, IgG and lysozyme. Res Commun Mol Pathol Pharmacol 102(1):15-28.
44. Sahin E, Grillo AO, Perkins MD, Roberts CJ. 2010. Comparative effects of pH and ionic strength on protein-protein interactions, unfolding, and aggregation for IgG1 antibodies. J Pharm Sci 99(12):4830-4848.
45. Rubin J, Linden L, Coco WM, Bommarius AS, Behrens SH. 2012. Salt-induced aggregation of a monoclonal human immunoglobulin G1. J Pharm Sci 102(2):377-386.
46. Xie M, Shahrokh Z, Kadkhodayan M, Henzel WJ, Powell MF, Borchardt RT, Schowen RL. 2003. Asparagine deamidation in recombinant human lymphotoxin: Hindrance by three-dimensional structures. J Pharm Sci 92(4):869-880.
47. Kossiakoff AA. 1988. Tertiary structure is a principal determinant to protein deamidation. Science 240(4849):191-194.
48. Meyer JD, Ho B, Manning MC. 2002. Effects of conformation on the chemical stability of pharmaceutically relevant polypeptides. Pharm Biotechnol 13:85-107.
49. Sadakane Y, Fujii N, Nakagomi K. 2011. Determination of rate constants for beta-linkage isomerization of three specific aspartyl residues in recombinant human alphaA-crystallin protein by reversed-phase HPLC. J Chromatogr B 879(29):3240-3246.
50. Xie M, Schowen RL. 1999. Secondary structure and protein deamidation. J Pharm Sci 88(1):8-13.
51. Houde D, Peng Y, Berkowitz SA, Engen JR. 2010. Post-translational modifications differentially affect IgG1 conformation and receptor binding. Mol Cell Proteomics 9(8):1716-1728.
52. Burkitt W, Domann P, O'Connor G. 2010. Conformational changes in oxidatively stressed monoclonal antibodies studied by hydrogen excha-nge mass spectrometry. Protein Sci 19(4):826-835.
53. Majumdar R, Manikwar P, Hickey JM, Samra HS, Sathish HA, Bishop SM, Middaugh CR, Volkin DB, Weis DD. 2013. Effects of salts from the Hofmeister series on conformational stability, aggregation propensity, and local flexibility of an IgG1 monoclonal antibody. Biochemistry 52(19):3376-3389.
54. Kaisheva EA, Gupta S, Flores-nate A. 2004. Patent WO2004/039337 A2. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization.
55. Bondarenko P, Chelius D, Matsumura M, McAuley A, Rehder D. 2010. Patent US7705132. Stable polypeptide formulations.
56. Ionescu RM, Vlasak J, Price C, Kirchmeier M. 2008. Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. J Pharm Sci 97(4):1414-1426.
57. Welfle K, Misselwitz R, Hausdorf G, Hohne W, Welfle H. 1999. Conformation, pH-induced conformational changes, and thermal unfolding of anti-p24 (HIV-1) monoclonal antibody CB4-1 and its Fab and Fc fragments. Biochim Biophys Acta 1431(1):120-131.
58. Schaefer M, Sommer M, Karplus M. 1997. pH-dependence of protein stability: Absolute electrostatic free energy differences between conformations. J Phys Chem B 101(9):1663-1683.
59. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. 2010. Stability of protein pharmaceuticals: An update. Pharm Res 27(4):544-575.
60. Volkin DB, Mach H, Middaugh CR. 1997. Degradative covalent reactions important to protein stability. Mol Biotechnol 8(2):105-122.
61. Lowe D, Dudgeon K, Rouet R, Schofield P, Jermutus L, Christ D. 2011. Aggregation, stability, and formulation of human antibody therapeutics. Adv Protein Chem Struct Biol 84:41-61.
62. Wang W, Singh S, Zeng DL, King K, Nema S. 2007. Antibody structure, instability, and formulation. J Pharm Sci 96(1):1-26.